Product Description
Klaire-SFI Ther-Biotic Target B2 supports breast health during lactation and immune health in infants. Provides a safe and eff ective approach to preventing, reducing, and resolving lactation discomforts and dysbiosis. Breast milk provides all the nutrients and components necessary for proper infant development and growth. Moreover, breastfeeding also appears to have important effects on the infant microbiome that can be determinative of later health. Enteric-breast circulation occurs and is higher in late pregnancy and lactation. This may explain why orally administered probiotic supplements can directly influence health of breast microbiota. Although the study of probiotics in human milk is a relatively recent field of research, the existence of a human milk microbiome has been described for more than a decade. Conventional therapies for lactation discomfort are ineff ective and carry many disadvantages, including side eff ects, maternal dysbiosis, loss of maternal-infant bonding, and undesirable eff ects on infant immune system maturation. The advent of safe, eff ective support options for maternal breast and infant immune health should be a matter of intense interest for obstetricians, lactation consultants, nurses, midwives, and other allied health professionals who provide primary care for breastfeeding mothers.
Recommended Use: 1 capsule, 1 to 3 times daily (3 to 9 billion CFU) or as directed by a healthcare professional.
PLEASE NOTE: These probiotics are designed with higher potency than on the label for them to be transported to any destination safely. This overage compensates for any transit time, items left unrefrigerated, or left out in hot weather. It takes these probiotics about two weeks in 120 temperatures continuously, to start to lose any potency at a very slow decline. Do however refrigerate the product as soon as it arrives.
Related Articles
Label Information
Klaire-SFI Ther-Biotic Target B21 capsule contains:
- Lactobacillus fermentum (3 billion CFU) 30 mg
- Potassium 5 mg